Concentra Group Holdings Parent's Q2 revenue up 15.2%, beats estimates

Concentra group Parent

07/08/2025 21:45

Overview

Concentra Q2 2025 revenue rises 15.2%, beating analyst expectations, per LSEG data

Adjusted EBITDA for Q2 2025 beats consensus, reflecting operational efficiencies

Company raises FY 2025 guidance, indicating confidence in future performance

Outlook

Concentra raises FY 2025 revenue guidance to $2.13 bln-$2.16 bln

Company expects FY 2025 Adjusted EBITDA of $420 mln-$430 mln

Concentra targets net leverage ratio of 3.5x by year-end

Company maintains FY 2025 capital expenditure forecast at $80 mln-$90 mln

Result Drivers

PATIENT VISITS - Increase in patient visits by 9.5% contributed to revenue growth

ACQUISITIONS - Integration of Nova Medical Centers and Pivot Onsite Innovations drove operational efficiencies

REVENUE PER VISIT - Revenue per visit rose 4.4%, supporting top-line growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$550.78 mln
$537.40 mln (8 Analysts)
Q2 EPS
$0.35
Q2 Net Income
$46.19 mln
Q2 Adjusted EBITDA
Beat
$115 mln
$112.70 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Concentra Group Holdings Parent Inc is $28.00, about 28.8% above its August 6 closing price of $19.94

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nBw3F6h37a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)